Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries a substantial risk of severe and prolonged illness; treatment options are currently limited. We assessed the efficacy and safety of inhaled nebulised interferon beta-1a (SNG001) for the treatment of patients a...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, Phillip D, Marsden, Richard J, Tear, Victoria J, Brookes, Jody, Batten, Toby N, Mankowski, Marcin, Gabbay, Felicity J, Davies, Donna E, Holgate, Stephen T, Ho, Ling-Pei, Clark, Tristan, Djukanovic, Ratko, Wilkinson, Tom M A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836724/
https://www.ncbi.nlm.nih.gov/pubmed/33189161
http://dx.doi.org/10.1016/S2213-2600(20)30511-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836724/
https://www.ncbi.nlm.nih.gov/pubmed/33189161
http://dx.doi.org/10.1016/S2213-2600(20)30511-7

Ejemplares similares